

---

## Integrum Q1 - Miss on sales

Redeye argues that the relatively disappointing quarterly figures increase the likelihood of the shareholders accepting the SEK44 bid offer. The two remaining weeks of the acceptance period offer investors a compelling IRR

**Read more and download the Research Update.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

**Integrum Q1 - Miss on sales**